目前，尚未确定一种可靠的肺腺癌（LUAD）早期预后标志物，该癌种为最常见的恶性肿瘤。最近的研究表明，溶酶体破裂参与了癌症的迁移、进展和免疫微环境形成。我们对溶酶体破裂进行了生物信息学分析，以研究溶酶体相关基因（LRGs）是否在LUAD中起关键作用。该分析确定了23个LRGs。通过Cytoscape可视化，确定了10个核心基因（CCNA2、DLGAP5、BUB1B、KIF2C、PBK、CDC20、NCAPG、ASPM、KIF4A、ANLN）。以这23个LRGs为基础，我们建立了一个新的风险评分规则，将LUAD患者分为高风险和低风险组，并通过受试者工作特征曲线验证了风险评分的准确性，同时建立了一个评估临床患者的诺模图。根据肿瘤突变负荷、免疫细胞浸润分析和药物敏感性，评估了高风险和低风险组之间的免疫治疗效果。途径富集分析发现，在LUAD患者中，溶酶体与葡萄糖代谢、氨基酸代谢和免疫反应密切相关。溶酶体可能是一种新的治疗靶点，并为治疗和管理LUAD患者提供了新的方向和思路。版权所有 © 2023年作者。 Wolters Kluwer Health, Inc. 发表。

Currently, a reliable early prognostic marker has not been identified for lung adenocarcinoma (LUAD), the most common malignancy. Recent studies demonstrated that lysosomal rupture is involved in cancer migration, progression, and immune microenvironment formation. We performed a bioinformatics analysis of lysosomal rupture to investigate whether lysosome-related genes (LRGs) are key in LUAD. The analysis identified 23 LRGs. Cytoscape visualization identified 10 core genes (CCNA2, DLGAP5, BUB1B, KIF2C, PBK, CDC20, NCAPG, ASPM, KIF4A, ANLN). With the 23 LRGs, we established a new risk scoring rule to classify patients with LUAD into high- and low-risk groups and verified the accuracy of the risk score by receiver operating characteristic curves and established a nomogram to evaluate clinical patients. Immunotherapy effectiveness between the high- and low-risk groups was evaluated based on the tumor mutational burden and analyses of immune cell infiltration and drug sensitivity. Pathway enrichment analysis revealed that lysosomes were closely associated with glucose metabolism, amino acid metabolism, and the immune response in patients with LUAD. Lysosomes are a likely new therapeutic target and provide new directions and ideas for treating and managing patients with LUAD.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.